文献速递胸部肿瘤

恶性胸膜间皮瘤接受肿瘤定向手术的长期生存结局:倾向评分匹配分析

Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
PubMed 文献 · J Clin Oncol · 2017-08-17

基于美国国家癌症数据库2004至2014年经显微镜确诊的20,561例恶性胸膜间皮瘤患者,按1:2倾向评分匹配后纳入6,645例分析。肿瘤定向手术、化疗和放疗均与生存改善独立相关(HR分别为0.77、0.74、0.88),手术为基础的多模式治疗较单纯手术生存更优,三联治疗估计效应最大(HR 0.52)。

要点

  • 肿瘤定向手术、化疗、放疗均与生存改善独立相关,HR分别为0.77、0.74、0.88。
  • 手术为基础的多模式治疗较单纯手术生存改善,各多模式方案间无显著差异。
  • 上皮亚型接受三联治疗者中位生存由14.5个月延长至23.4个月。

核心结论

  • 恶性胸膜间皮瘤侵袭性强、进展迅速且致死快。
  • 手术为基础的多模式治疗与生存改善相关,可能为经过仔细筛选的患者带来治疗获益。

研究设计与样本

  • 利用美国国家癌症数据库(2004至2014年)识别经显微镜确诊的恶性胸膜间皮瘤患者。
  • 共纳入20,561例患者,按1:2进行倾向评分匹配后队列为6,645例。
  • 采用Cox比例风险回归模型识别生存预测因素,并以Kaplan-Meier法计算中位生存。

主要发现

  • 匹配队列6,645例中,2,166例未接受治疗,2,015例仅接受化疗,850例仅接受肿瘤定向手术,988例接受手术联合化疗,274例接受三联治疗,其余352例接受其他手术、放疗或化疗组合。
  • 30天和90天死亡率分别为6.3%和15.5%。
  • 肿瘤定向手术、化疗和放疗均与生存改善独立相关,风险比分别为0.77、0.74和0.88。
  • 分层分析显示,手术为基础的多模式治疗较单纯手术生存改善,各手术为基础的多模式治疗之间无显著差异。
  • 三联治疗(肿瘤定向手术、化疗和放疗联合)的估计效应最大,风险比为0.52;上皮亚型接受三联治疗者中位生存由14.5个月延长至23.4个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Small observational studies have shown a survival advantage to undergoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if these results are generalizable. Our purpose was to evaluate survival after treatment of MPM with cancer-directed surgery and to explore the effect surgery interaction with chemotherapy or radiation therapy on survival by using the National Cancer Database. Patients and Methods Patients with microscopically proven MPM were identified within the National Cancer Database (2004 to 2014). Propensity score matching was performed 1:2 and among this cohort, a Cox proportional hazards regression model was used to identify predictors of survival. Median survival was calculated by using the Kaplan-Meier method. Results Of 20,561 patients with MPM, 6,645 were identified in the matched cohort, among whom 2,166 underwent no therapy, 2,015 underwent chemotherapy alone, 850 underwent cancer-directed surgery alone, 988 underwent surgery with chemotherapy, and 274 underwent trimodality therapy. The remaining 352 patients underwent another combination of surgery, radiation, or chemotherapy. Thirty-day and 90-day mortality rates were 6.3% and 15.5%. Cancer-directed surgery, chemotherapy, and radiation therapy were independently associated with improved survival (hazard ratio, 0.77, 0.74, and 0.88, respectively). Stratified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival compared with surgery alone, with no significant difference between surgery-based multimodality therapies; however, the largest estimated effect was when cancer-directed surgery, chemotherapy, and radiation therapy were combined (hazard ratio, 0.52). For patients with the epithelial subtype who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 months. Conclusion MPM is an aggressive and rapidly fatal disease. Surgery-based multimodality therapy was associated with improved survival and may offer therapeutic benefit among carefully selected patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nelson DB, Rice DC, Niu J, et al. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017. PMID: 28817374. doi:10.1200/JCO.2017.73.8401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。